Canada-based pharmaceutical company ESSA Pharma Inc (NASDAQ:EPIX) on Monday issued a statement clarifying the period of due bill trading in connection with its USD80m return of capital distribution.
The company confirmed that shareholders received approximately USD1.6910318 per common share on 22 August 2025, in connection with the wind-up of its business following a transaction with XenoTherapeutics Inc, a non-profit biotechnology company.
In its 14 August 2025 release, Essa Pharma incorrectly stated that common shares would trade with due bills through 25 August 2025. The correct period was from 19 August 2025 through 22 August 2025.
Shares began trading on an ex-dividend basis on 25 August 2025, the first business day after the payment date. The company emphasised that no due bills were attached to trades on that date.
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli